Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
Enfortumab vedotin showed significant tumor shrinkage in the primary tumor, lung metastases, and lymph node metastases, whereas the durability of tumor shrinkage was limited in the primary tumor.
Authors
- Tatsuya Kawamura (ORCID: https://orcid.org/0000-0001-9382-1294)
- Shigekatsu Maekawa (ORCID: https://orcid.org/0000-0003-4620-2831)
- Jun Sugimura (ORCID: https://orcid.org/0000-0003-3587-5395)
- Renpei Kato (ORCID: https://orcid.org/0000-0001-6089-7620)
- Arisa Machida (ORCID: https://orcid.org/0000-0002-8536-3534)
- Wataru Obara
- Ei Shiomi (ORCID: https://orcid.org/0000-0002-7221-4628)
- Ayato Ito (ORCID: https://orcid.org/0000-0002-6573-3999)
- Daiki Ikarashi (ORCID: https://orcid.org/0000-0001-8088-2848)
- Mitsugu Kanehira (ORCID: https://orcid.org/0000-0001-8811-8158)
- Yumeka Arakawa
- Keita OGASAWARA
Institutions
- Iwate Medical University (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-29
- DOI
- https://doi.org/10.3389/fonc.2024.1493922
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01